Monday, February 18, 2019
News

Aurobindo Pharma receives USFDA approval for azithromycin oral suspension

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Mumbai | Thursday, Oct 11 2018 IST
Pharma major Aurobindo Pharma Limited said that company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Azithromycin OralSuspension 100 mg /5 mL and 200 mg/5 mL. Azithromycin oral suspension IS a generic version of Pfizer Inc's Zithromax oral suspension. The product will be launched in November 2018, company said in a filing with BSE.

Azithromycin oral suspension is indicated for the treatment of patients with mild to moderate infections. The approved product has an estimated market size of USD 71 million for the twelve months ending August 2018, according to IQVIA.

This is the 125th Abbreviated New Drug Application (ANDA) (including 11 tentative approvals) to be approved out of Unit III formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 386 ANDA approvals (357 Final approvals including 19 from Aurolife Pharma LLC and 29 tentative approvals) from USFDA.

UNI JS NV SV 1313

-- (UNI) -- C-1-DL0171-1547298.Xml

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
One jawan injured in encounter with Naxa...
Ahead of polls, YSRCP chief Jagan Reddy ...
J-K: Encounter between security forces a...
Odisha CM lays foundation stone for Canc...
Hyderabad gets its first Trompe-loeil a...
2 Youth Cong workers hacked to death in ...
More...    
 
 Top Stories
Poland PM cancels Israel trip after... 
9 dead in Boko Haram attack in Nige... 
Odisha CM lays foundation stone for... 
Mike Posner stays silent to preserv... 
Iran summons Pak envoy over suicide... 
J-K: Encounter between security for... 
Assad says Syrian constitution not ... 
Ahead of polls, YSRCP chief Jagan R...